-

12:52:48 PM

BTAI Stock News

BTAI - BioXcel Therapeutics Inc

05/20/22 7:00 AM

Nasdaq : BTAI

low float

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D.,

RHEA-AI

neutral

05/09/22 7:00 AM

Nasdaq : BTAI

earningslow float

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitation

RHEA-AI

very positive

05/05/22 7:00 AM

Nasdaq : BTAI

conferenceslow float

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D.,

RHEA-AI

neutral

05/03/22 7:00 AM

Nasdaq : BTAI

clinical triallow float

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company

RHEA-AI

very positive

04/26/22 7:00 AM

Nasdaq : BTAI

conferencesearningslow float

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, today announced that

RHEA-AI

neutral

04/19/22 7:05 AM

Nasdaq : BTAI

low float

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lead pipeline asset, BXCL701,

RHEA-AI

very positive

04/19/22 7:00 AM

Nasdaq : BTAI

low float

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”),

RHEA-AI

very positive

04/06/22 7:00 AM

Nasdaq : BTAI

fda approvallow float

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder 1 IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 mcg doses in pivotal studies

RHEA-AI

neutral

03/10/22 7:04 AM

Nasdaq : BTAI

earningslow float

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Submitted IND to evaluate BXCL501 as adjunctive treatment for major

RHEA-AI

positive

03/09/22 7:00 AM

Nasdaq : BTAI

conferenceslow float

BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D.,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

BTAI Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.bioxceltherapeutics.com
CeoVimal Mehta
Security nameBioXcel Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees50
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address555 Long Wharf Dr
StateConnecticut
CityNew Haven
Zip06511-6107
CountryUnited States
Phone12036438060

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.